American National Bank & Trust Co. VA Purchases Shares of 2,915 Amgen Inc. (NASDAQ:AMGN)

American National Bank & Trust Co. VA purchased a new stake in Amgen Inc. (NASDAQ:AMGN) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,915 shares of the medical research company’s stock, valued at approximately $829,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. BOK Financial Private Wealth Inc. acquired a new stake in shares of Amgen during the fourth quarter worth about $29,000. United Community Bank acquired a new stake in shares of Amgen during the fourth quarter worth about $29,000. Planned Solutions Inc. acquired a new stake in shares of Amgen during the fourth quarter worth about $30,000. Delos Wealth Advisors LLC increased its position in shares of Amgen by 2,500.0% during the fourth quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after purchasing an additional 100 shares in the last quarter. Finally, Hartford Financial Management Inc. increased its position in shares of Amgen by 56.9% during the fourth quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock worth $33,000 after purchasing an additional 41 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Price Performance

Shares of NASDAQ:AMGN traded down $1.39 during trading on Thursday, hitting $309.38. 1,000,711 shares of the stock were exchanged, compared to its average volume of 2,340,821. The company has a fifty day moving average price of $303.81 and a two-hundred day moving average price of $292.91. The company has a market cap of $165.96 billion, a PE ratio of 44.20, a P/E/G ratio of 2.81 and a beta of 0.58. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. Amgen Inc. has a 12-month low of $218.44 and a 12-month high of $329.72.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, topping the consensus estimate of $3.76 by $0.20. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. The company’s quarterly revenue was up 22.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.98 EPS. On average, analysts forecast that Amgen Inc. will post 19.47 EPS for the current year.

Insider Transactions at Amgen

In other news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the sale, the senior vice president now owns 9,883 shares of the company’s stock, valued at approximately $3,094,268.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.69% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. Raymond James assumed coverage on Amgen in a research report on Thursday, March 28th. They set a “market perform” rating on the stock. Argus raised their price target on Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. BMO Capital Markets raised their price target on Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. TD Cowen lowered their price target on Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a report on Wednesday, April 17th. Finally, Mizuho raised their price target on Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, Amgen has a consensus rating of “Moderate Buy” and a consensus target price of $307.35.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.